Members of the JAK family are the targets of several marketed and clinical-stage drugs for cancer and autoimmune diseases, although there are currently no marketed products specifically targeting TYK2. In clinical trials, there has been strong clinical validation (from BMS and Pfizer) for TYK2 and TYK2/JAK1 in psoriasis and psoriatic arthritis. These companies are also undertaking mid-stage clinical trials of TYK2 and TYK2/JAK1 inhibitors for lupus, ulcerative colitis, Crohn’s disease, vitiligo and other autoimmune diseases.
Sareum's TYK2/JAK1 preclinical devlopment candidate molecule, SDC-1801, demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3), compelling activity in disease models of psoriasis and rheumatoid arthritis, the potential for once-daily oral dosing and a good early safety profile. Closely related molecules, including SAR-20347, also show good activity in models of inflammatory bowel disease and systemic lupus erythematosus (lupus). These attributes strongly support the progression of SDC-1801 through preclinical development and, pending satisfactory progress, advancement into human clinical trials, which could begin in 2022.
Preclinical development candidate SDC-1801 was nominated from a novel series of compounds designed and identified by Sareum following a rigorous selection process. The company is also completing its assessment of further dual TYK2/JAK1 inhibitors for the potential treatment of certain cancers and/or as a back-up to SDC-1801.
Additionally, there is strong scientific evidence for the roles of TYK2/JAK1 role in modulating the severe inflammatory responses and respiratory symptoms arising from coronavirus and other viral infections. Several JAK family inhibitors have been approved or are in clinical trials for use against Covid-19. Further information on Sareum's TYK2/JAK1 Covid-19 research programme can he found here.
Find out more by getting in touch at